GlassScriptPhysician profile
Nancy R Berman
NPI 1174530398
$38,507.71
in general payments reported to CMS, 2019-2025
19 companies · $11K in 2025
The $11K reported for 2025 was more than what 99% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,493 · 2022: $5,418 · 2023: $13K · 2024: $4,965 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Consulting Fee: $8,648 · Travel and Lodging: $5,694 · Food and Beverage: $3,369.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,884.50 |
| Consulting Fee | $8,648.00 |
| Travel and Lodging | $5,694.36 |
| Food and Beverage | $3,369.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $16,704.68 | 2022-2025 | Veozah |
| Merck Sharp & Dohme LLC | $8,450.49 | 2024-2025 | M-M-R II |
| Dysis Medical, INC. | $2,850.00 | 2021 | |
| Myovant Sciences INC. | $2,538.16 | 2022 | |
| Pfizer INC. | $2,480.00 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,986.60 | 2025 | |
| Scynexis, INC. | $1,072.43 | 2022 | |
| Amgen INC. | $756.24 | 2021-2025 | Evenity, Prolia, Prolia |
| Lupin INC. | $400.00 | 2021 | |
| Sumitomo Pharma America, INC. | $381.16 | 2023-2025 | Myfembree, Gemtesa |
| Lilly USA, LLC | $312.27 | 2024-2025 | Zepbound, Jardiance, Kisunla |
| Novo Nordisk INC | $240.50 | 2021-2025 | Wegovy |
| Astellas Pharma Global Development | $119.72 | 2023 | Veozah |
| Abbott Laboratories | $81.52 | 2022-2023 | Freestyle Libre 3 |
| Abbvie INC. | $52.86 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $47.05 | 2023 | Nexplanon |
| Abiomed | $18.89 | 2023 | Impella |
| Glaxosmithkline, LLC. | $15.14 | 2025 | Arexvy, Shingrix |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Berman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.